Drug screening model meets cancer organoid technology
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-11-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320303326 |
| _version_ | 1828469627827519488 |
|---|---|
| author | Chen Liu Tianyu Qin Yuhan Huang Yuan Li Gang Chen Chaoyang Sun |
| author_facet | Chen Liu Tianyu Qin Yuhan Huang Yuan Li Gang Chen Chaoyang Sun |
| author_sort | Chen Liu |
| collection | DOAJ |
| description | Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening. |
| first_indexed | 2024-12-11T04:41:51Z |
| format | Article |
| id | doaj.art-1d8056a249ec4e2a9ab21974254fc772 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-11T04:41:51Z |
| publishDate | 2020-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-1d8056a249ec4e2a9ab21974254fc7722022-12-22T01:20:36ZengElsevierTranslational Oncology1936-52332020-11-011311100840Drug screening model meets cancer organoid technologyChen Liu0Tianyu Qin1Yuhan Huang2Yuan Li3Gang Chen4Chaoyang Sun5Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaCorresponding author.; Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaTumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.http://www.sciencedirect.com/science/article/pii/S1936523320303326Cancer organoidDrug screeningPrecision therapy |
| spellingShingle | Chen Liu Tianyu Qin Yuhan Huang Yuan Li Gang Chen Chaoyang Sun Drug screening model meets cancer organoid technology Translational Oncology Cancer organoid Drug screening Precision therapy |
| title | Drug screening model meets cancer organoid technology |
| title_full | Drug screening model meets cancer organoid technology |
| title_fullStr | Drug screening model meets cancer organoid technology |
| title_full_unstemmed | Drug screening model meets cancer organoid technology |
| title_short | Drug screening model meets cancer organoid technology |
| title_sort | drug screening model meets cancer organoid technology |
| topic | Cancer organoid Drug screening Precision therapy |
| url | http://www.sciencedirect.com/science/article/pii/S1936523320303326 |
| work_keys_str_mv | AT chenliu drugscreeningmodelmeetscancerorganoidtechnology AT tianyuqin drugscreeningmodelmeetscancerorganoidtechnology AT yuhanhuang drugscreeningmodelmeetscancerorganoidtechnology AT yuanli drugscreeningmodelmeetscancerorganoidtechnology AT gangchen drugscreeningmodelmeetscancerorganoidtechnology AT chaoyangsun drugscreeningmodelmeetscancerorganoidtechnology |